Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional) | PAR-19-389 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and… More | ||
| Notice of Availability of Administrative Supplements to Support Acquisition and Annotation of Biospecimens from Racial/Ethnically Diverse Cancer Patients for the Development of Models for the Human Cancer Models Initiative (HCMI) | NOT-CA-18-076 | NCI | N/A | Notice Availability Administrative Supplements Support Acquisition Annotation Biospecimens Racial/Ethnically Diverse Cancer Patients the Development Models the Human Cancer Models Initiative HCMI)… More | |
| Revision Applications for Mechanisms of Drug Resistance (R01 Clinical Trials Not Allowed) | RFA-CA-19-049 | NCI | This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support… More |
||
| The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required) | PAR-21-318 | NCI | This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to… More | ||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) | RFA-CA-21-011 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects. The… More | ||
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | PAR-20-313 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "… More | ||
| Co-infection and Cancer (R01 Clinical Trial Not Allowed) | PAR-20-062 | NCI | This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be… More |
||
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | PAR-19-325 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic… More | ||
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) | PAR-19-350 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer… More | ||
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-21-006 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the… More |